• +33 (0)3 74 00 81 00

  • philippe.froguel@cnrs.fr

  • PreciDIAB, Pôle Recherche,
    1 place de Verdun 59045 Lille Cedex - France

PreciDIAB leaders

Teams involved in the IHU project

Scientific Advisory Board (SAB) of PreciDIAB

Hans Haring

Munich, Chairman
Founder of the national German center for diabetes research (DZD). World leader in diabetes clinical research

Juleen Zierath

Karolinska and Copenhagen
Scientific director of Novo-Nordisk foundation center for diabetes research. World leader in epigenetics of diabetes and effect of sport on muscle at Karolinska University. Chair of Nobel Prize committee in Medicine, President of European Association for the Study of Diabetes (EASD)

Susan Mandrup

Odense
World leading expert in system biology of insulin action

Oluf Pedersen

Copenhagen
Pioneer in genetics and metagenomics of diabetes. Expert in clinical research, first to show that T2D complications rates can be prevented (Steno 2 study). Former VP of Novo Nordisk

Raul Urrutia

Milwaukee
Expert in systems biology in pancreatic cancer and pancreatic morphogenesis, Director of University of Wisconsin Precision Medicine center

Jose Florez

Harvard
Endocrinologist at Massachusetts General Hospital, Head of diabetes program at Broad Institute, expert in genomics of diabetes clinical studies

15 Key Workpackages leaders of PreciDIAB

The projects funded will be those responding to, and able to solve, a known clinical problem, with a potential of short term clinical innovation and exploitation in liaison with the private sector.

The 4 basic research WPs – WP1-4:

will elucidate the mechanisms underlying the unresolved problems

will build the tools and protocols enabling efficient patients and population stratification,

and will bring rational and realistic avenues for the next 5 WPs – WP5-9 – to develop medical research projects leading to prevention and care.

The best-evaluated research outputs will be disseminated – WP12 – and when appropriate exploited by the private sector through WP10 and WP11. This straightforward multidisciplinary translational path will be manned by the highly skilled staff we will train (in English) to the best standards of excellence in our 3 international schools – WP13-15 – , on translational diabetes research (MD/PhD graduate school  WP13), clinical diabetes research and precision medicine. First time working together, these schools will provide the skilled workforce both public/private sectors need to succeed in the next 10 yrs.

WP1
Identifying diabmarkers signatures of subclinical diabetes

 

Identifying predictive diabmarkers of pancreatic β-cell damage/failure, of insulin resistance, of neuroendocrine dysfunction in specific prospective cohorts that are not (yet) diabetic.

Philippe Froguel

Professor of Endocrinology, Lille University Hospital
Professor of Genomic Medicine, Imperial College London Faculty of Medicine

WP2
Identifying diabmarkers of complications, comorbidities and disabilities

 

Bring breakthroughs into the assessment of complications and comorbidities risk. Guide the management of diabetic patients in dangerous conditions to reduce mortality/disability.

Bart Staels

Head of Inserm Unit UMR1011, Institut Pasteur de Lille
Professor, Faculty of Pharmacy, University of Lille 2

Amélie Bonnefond

Senior Research Scientist (CR1-Inserm), CNRS UMR8199, Lille
Honorary Senior Research Scientist, Department of Genomics of Common Disease, Imperial College London

WP3
Genomic diabetic medicine from diagnosis to personal treatment

 

Establish and bring to medical diagnosis reliable NGS protocols for the identification of monofactorial forms of diabetes or obesity. Identify and phenotypically characterize new diabetes and obesity genes, and to discover therapeutic solutions tailored for each genetic subtype.

Benoit Deprez

PRCE, University of Lille
Director of the Drug Discovery Centre, Institut Pasteur de Lille

WP4
Developing groundbreaking preventive/therapeutic innovative solutions

 

Offer easy tools for personal nutrition of (pre)diabetic patients. Develop a more efficient drug discovery process taking into account interindividual response differences and engaging patients. Elucidate metabolic surgery T2D remission and to develop next-generation Msurgery.

WP5
Raising awareness & offering tailored prevention to at risk populations

 

Recognize early life diabetes risk factors, and to use subclinical diabetes signatures with new risk markers obtained from WP1 to develop focused and tailored preventive interventions.

Philippe Deruelle

Professor of Obsterics and Gynecology, University of Lille, School of Medicine

WP6
Creating an intelligent 21st
century university hospital without walls

 

Demonstrate that diabetic patients should greatly benefit from a highly integrated patient-centered network managed by a multidisciplinary team to position the IHU as the EU leader in connected diabetes care. Perform cost-effectiveness analyses of IHU clinical studies. Bring Artificial Intelligence (AI) in hospital to analyze patients’ medical record.

Jean-Baptiste Beuscart

Assistant Professor in Geriatrics, University of Lille and CHU Lille

Marie-Christine Vantyghem

Professor of Endocrinology, Diabetology, Metabolism, CHU Lille, Inserm Unit 1190 Translational Research in Diabetes

WP7
Focus on innovation that changes uncontrolled diabetic patients’ life

 

Make PreciDIAB the European leader in therapeutic innovation against diabetes and complications and for prevention. Develop world class diabetes biotherapy and clinical trials.

Jean-Louis Nandrino

Professor of Psychopathology, UMR-CNRS 9193 University of Lille
Scientific advisor for the High Council for Evaluation of Research and Higher Education (Hcéres), HCERES, Paris

WP8
Targeting the human factor for long-term diabetes treatment success

 

Develop tailored physical activity and psychological training for (pre)diabetic and diabetic patients and to their family

WP9
Preventing disability in the complex diabetic patient

 

Identify prognostic markers of early mortality and disability. Test specifically tailored preventive strategies. Implement in daily clinical care a multidisciplinary approach dedicated to the complex diabetic patient. The goal is to significantly reduce diabetes death and disability.

Charlotte Cordonnier

Head of department of neurology & stroke centre, Lille University Hospital
Professor of Neurology, University of Lille

WP10
Licensing and startup creation for optimal transfer

 

Implement a simple and cost-effective transfer policy enabling PreciDIAB founders and partners to value their R&D investments in diabetes and co morbidities through licensing out opportunities and creation of dedicated startups.

Gilles Pulvermuller

Technology Transfer Officer, EGID, University of Lille

Etienne Vervaecke

General Manager, EURASANTE, Lille
General Manage, NHL Competitiveness Cluster, Lille

WP11
PreciDIAB Initiative a tool for gold nugget discovery & PPP fund raising

 

Set up an innovative fast-moving tool to foster the transfer of discoveries into products for diabetes care. Assess “technical” readiness level of “transferable” IHU projects and outcomes. Set up world class consortia and efficiently respond to national, and international calls. Launch cost efficient fundraising and donations actions. Exchange and share experience/knowledge with industry partners on new market trends and regulatory guidelines in diabetes field.

Pierre Fontaine

Head of department of endocrinology, CHU Lille
Professor of endocrinology and diabetology, University of Lille

WP12
PreciDIAB networks: disseminating innovation beyond IHU

 

Develop concerted actions with patients’ and professionals’ national and international associations and major diabetes institutes worldwide to disseminate the best IHU outcomes.

WP13
Excellence in Diabetes Science International Graduate School

 

Establish the first European graduate school in diabetes with a PhD program customized for MDs, for pharmacists and biomedical students seeking international careers in academia, biotech, industry, government administration or health agencies.

Amar Abderrahmani

Professor of Cell and Molecular Biology, Lille University
Deputy Director of CNRS UMR 8199, CNRS/Lille University/Institut Pasteur de Lille

WP14
Excellence in Clinical Research (ECR) Diabetes School

 

Provide all necessary know-how and methodologies for high quality clinical studies. Help access rewarding Clinical Research Professional jobs in diabetes field.

Dominique Deplanque

Professor of clinical Pharmacology, University and CHU of Lille
Medical Coordinator of Health Research Department, CHU Lille

Toby Andrew

Lecturer in Human Genetics, Imperial College of London

WP15
Excellence in Precision Medicine (EPM) Diabetes School

 

Provide state of art “education and training” in genomic medicine and precision medicine to medical practitioners (MDs and pharmacists), RAs in genetic labs, and other professionals involved in precision medicine.

The projects funded will be those responding to, and able to solve, a known clinical problem, with a potential of short term clinical innovation and exploitation in liaison with the private sector.

The 4 basic research WPs will:

  • elucidate the mechanisms underlying the unresolved problems,
  • build the tools and protocols enabling efficient patients and population stratification,
  • and bring rational and realistic avenues for the next 5 WPs to develop medical research projects leading to prevention and care.

The best-evaluated research outputs will be disseminated (WP12) and when appropriate exploited by the private sector through WP10 and WP11.

This straightforward multidisciplinary translational path will be manned by the highly skilled staff we will train (in English) to the best standards of excellence in our 3 international schools (WP 13-15), on translational diabetes research (MD/PhD graduate school), clinical research and precision diabetes medicine. First time working together, these schools will provide the skilled workforce both public/private sectors need to succeed in next 10 years.

©Eurasanté Copyright 2017. All rights reserved.